Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfanitran, 65642-65643 [2010-27010]
Download as PDF
<![CDATA[
65642
Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 21, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–27008 Filed 10–25–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
emcdonald on DSK2BSOYB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; HIV/
AIDS Behavioral Treatment Intervention and
Services Development-Member Conflict.
Date: November 12, 2010.
Time: 9:30 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call)
Contact Person: Enid Light, PhD, Scientific
Review Officer, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center, 6001
Executive Boulevard, Room 6132, MSC 9608,
Bethesda, MD 20852, 301–443–3599,
elight@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
VerDate Mar<15>2010
18:09 Oct 25, 2010
Jkt 223001
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: October 18, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–26959 Filed 10–25–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Amended Notice
of Meeting
Notice is hereby given of a change in
the meeting of the Council of Councils,
November 8, 2010, 9 a.m. to November
8, 2010, 3 p.m., National Institutes of
Health, Building 31, 31 Center Drive,
Bethesda, MD 20892 which was
published in the Federal Register on
September 30, 2010, 75 FR 60465.
This Federal Register Notice is
amended to add a Closed Session from
12:15 p.m. to 12:45 p.m. on November
8, 2010.
The meeting is partially closed to the
public.
Dated: October 20, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–27051 Filed 10–25–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Listing of Members of the
National Centers for Disease Control
and Prevention’s 2010 Performance
Review Board (PRB)
The Centers for Disease Control
and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC)
announces the persons who will serve
on the CDC’s 2010 Performance Review
Board. This action is being taken in
accordance with Title 5, U.S.C.,
4314(c)(4), which requires that members
of performance review boards be
appointed in a manner to ensure
consistency, stability, and objectivity in
performance appraisals and requires
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
that notice of the appointment of an
individual to serve as a member be
published in the Federal Register.
The following persons will serve on
the CDC Performance Review Board,
which is responsible for making
recommendations on performance
appraisal ratings, pay adjustments, and
performance awards for CDC’s Senior
Executive Service (SES) members:
Kevin Fenton (Co-Chair), Lynn Austin
(Co-Chair), Ed Hunter, Rima Khabbaz,
Crayton Lankford, Carolyn Black,
Christine Branche, Anne Haddix,
Barbara Harris, Jim Seligman, Walter
Harris, Hazel Dean, Bill Porter.
For further information about the CDC
Performance Review Board, contact the
Centers for Disease Control and
Prevention, Human Capital Management
Office, Human Capital Planning Branch,
1600 Clifton Road, NE., MS E–50,
Atlanta, GA 30333. Telephone (404)
498–6709 (not a toll free number).
Dated: October 20, 2010.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2010–26999 Filed 10–25–10; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0511]
Withdrawal of Approval of New Animal
Drug Applications; Aklomide;
Levamisole Hydrochloride; Nitromide
and Sulfanitran
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is withdrawing
approval of eight new animal drug
applications (NADAs). In a final rule
published elsewhere in this issue of the
Federal Register, FDA is amending the
animal drug regulations to remove
portions reflecting approval of these
NADAs.
DATES: Withdrawal of approval is
effective November 5, 2010.
FOR FURTHER INFORMATION CONTACT: John
Bartkowiak, Center for Veterinary
Medicine (HFV–212), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–9079,
e-mail: john.bartkowiak@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Fort
Dodge Animal Health, a Division of
Wyeth Holdings, a Wholly Owned
Subsidiary of Pfizer, Inc., 235 East 42d
SUMMARY:
E:\FR\FM\26OCN1.SGM
26OCN1
Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices
St., New York, NY 10017 has requested
that FDA withdraw approval of the eight
65643
NADAs listed in Table 1 of this
document.
TABLE 1
NADA No.
Product
NADA 11–141 ......................
NADA 14–250 ......................
NADA 34–536 ......................
UNISTAT–2 Type A medicated article ............................
NOVASTAT Type A medicated article ............................
ALKOMIX Type A medicated article ...............................
ALKOMIX–3 Type A medicated article ...........................
NOVASTAT–3 Type A medicated article ........................
NOVASTAT–W Soluble Powder .....................................
UNISTAT–3 Type A medicated article ............................
TRAMISOL Type A medicated article .............................
TRAMISOL Type A medicated article .............................
NADA
NADA
NADA
NADA
NADA
34–537
35–388
39–666
44–015
45–455
......................
......................
......................
......................
......................
Therefore, under authority delegated
to the Commissioner of Food and Drugs
and redelegated to the Center for
Veterinary Medicine, and in accordance
with § 514.116 Notice of withdrawal of
approval of application (21 CFR
514.116), notice is given that approval
of NADAs 11–141, 14–250, 34–536, 34–
537, 35–388, 39–666, 44–015, and 45–
455, and all supplements and
amendments thereto, is hereby
withdrawn, effective November 5, 2010.
In a final rule published elsewhere in
this issue of the Federal Register, FDA
is amending the animal drug regulations
to reflect the withdrawal of approval of
these NADAs.
Dated: October 8, 2010.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2010–27010 Filed 10–25–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5382–N–16]
Notice of Proposed Information
Collection for Public Comment: Survey
of Market Absorption of New
Multifamily Units
Office of Policy Development
and Research, HUD.
ACTION: Notice.
AGENCY:
The proposed information
collection requirement described below
will be submitted to the Office of
Management and Budget (OMB) for
approval as required by the Paperwork
Reduction Act of 1995. The Department
is soliciting public comments on the
subject proposal.
DATES: Comments Due Date: December
27, 2010.
ADDRESSES: Interested persons are
invited to submit comments regarding
this proposal. Comments should refer to
emcdonald on DSK2BSOYB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
18:09 Oct 25, 2010
Jkt 223001
Established name of drug(s)
nitromide and sulfanitran
aklomide and sulfanitran
aklomide
aklomide, sulfanitran, and roxarsone
aklomide, sulfanitran, and roxarsone
aklomide and sulfanitran
nitromide, sulfanitran, and roxarsone
levamisole
levamisole
the proposal by name/or OMB Control
Number and should be sent to: Reports
Liaison Officer, Office of Policy
Development and Research, Department
of Housing and Urban Development,
451 7th Street SW., Room 8234,
Washington, DC 20410.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information or
copies of the proposed forms and
instructions submitted to OMB should
be directed to: Carolyn Lynch,
Economist, Housing and Demographic
Analysis Division, Office of Policy
Development and Research, Department
of Housing and Urban Development,
451 7th Street, SW., Washington, DC
20410; via telephone (202) 402–5910
(this is not toll-free number); via e-mail
at Carolyn.Lynch@hud.gov or to Robert
R. Callis, U.S. Census Bureau, Social,
Economic and Housing Statistics
Division, 4600 Silver Hill Road, Room
7H087, Washington, DC 20233; via
telephone (301) 763–5694 (this is not
toll-free number); via e-mail at
Robert.R.Callis@Census.gov.
SUPPLEMENTARY INFORMATION: The
Department of Housing and Urban
Development will submit the proposed
information collection package to OMB
for review as required by the Paperwork
Reduction Act of 1995 (44 U.S.C.
chapter 35, as amended).
I. Abstract: Description of the Need for
the Information and Proposed Use
The Survey of Market Absorption
(SOMA) provides the data necessary to
measure the rate at which new rental
apartments and new condominium
apartments are absorbed; that is, taken
off the market, usually by being rented
or sold, over the course of the first
twelve months following completion of
a building. The data are collected at
quarterly intervals until the twelve
months conclude, or until the units in
a building are completely absorbed. The
survey also provides estimates of certain
characteristics, including asking rent/
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
price, number of units, and number of
bedrooms. The survey provides a basis
for analyzing the degree to which new
apartment construction is meeting the
present and future needs of the public.
Additionally, beginning with new
construction in 2002, the survey
ascertains the number and degree of
services provided by ‘‘Assisted Living’’
type units.
II. Method of Collection
The methodology for collecting
information on the lease or sale of new
multifamily units involves contacting a
sample of new multifamily units by
telephone or in person.
III. Data
Title of Proposal: Survey of Market
Absorption of New Multifamily Units.
OMB Control Number: 2528–0013
(Expires 1/30/2011).
Form Number: H–31.
Type of Review: Regular Submission.
Members of affected public: Rental
Agents/Builders.
Estimated Number of Respondents:
12,000 yearly (maximum).
Estimated Time per Response: 20
minutes.
Frequency of Response: Four times
(maximum).
Estimated Total Annual Burden
Hours: 4,000 (12,000 × 20 minutes).
Estimated Total Annual Cost: The
only cost to respondents is that of their
time. The total estimated cost to do the
survey in FY 2011 is $943,000.
Respondent’s Obligation: Voluntary.
Legal Authority: The survey is taken
under Title 12, United States Code,
Section 1701Z.
IV. Request for Comments
This Notice is soliciting comments
from members of the public and affected
agencies concerning the proposed
information collection of information to:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
E:\FR\FM\26OCN1.SGM
26OCN1
]]>Agencies
[Federal Register Volume 75, Number 206 (Tuesday, October 26, 2010)]
[Notices]
[Pages 65642-65643]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-27010]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0511]
Withdrawal of Approval of New Animal Drug Applications; Aklomide;
Levamisole Hydrochloride; Nitromide and Sulfanitran
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval
of eight new animal drug applications (NADAs). In a final rule
published elsewhere in this issue of the Federal Register, FDA is
amending the animal drug regulations to remove portions reflecting
approval of these NADAs.
DATES: Withdrawal of approval is effective November 5, 2010.
FOR FURTHER INFORMATION CONTACT: John Bartkowiak, Center for Veterinary
Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240-276-9079, e-mail: john.bartkowiak@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, a Division of
Wyeth Holdings, a Wholly Owned Subsidiary of Pfizer, Inc., 235 East 42d
[[Page 65643]]
St., New York, NY 10017 has requested that FDA withdraw approval of the
eight NADAs listed in Table 1 of this document.
Table 1
------------------------------------------------------------------------
Established name of
NADA No. Product drug(s)
------------------------------------------------------------------------
NADA 11-141................. UNISTAT-2 Type A nitromide and
medicated article. sulfanitran
NADA 14-250................. NOVASTAT Type A aklomide and
medicated article. sulfanitran
NADA 34-536................. ALKOMIX Type A aklomide
medicated article. aklomide,
ALKOMIX-3 Type A sulfanitran, and
medicated article. roxarsone
NADA 34-537................. NOVASTAT-3 Type A aklomide,
medicated article. sulfanitran, and
roxarsone
NADA 35-388................. NOVASTAT-W Soluble aklomide and
Powder. sulfanitran
NADA 39-666................. UNISTAT-3 Type A nitromide,
medicated article. sulfanitran, and
roxarsone
NADA 44-015................. TRAMISOL Type A levamisole
medicated article.
NADA 45-455................. TRAMISOL Type A levamisole
medicated article.
------------------------------------------------------------------------
Therefore, under authority delegated to the Commissioner of Food
and Drugs and redelegated to the Center for Veterinary Medicine, and in
accordance with Sec. 514.116 Notice of withdrawal of approval of
application (21 CFR 514.116), notice is given that approval of NADAs
11-141, 14-250, 34-536, 34-537, 35-388, 39-666, 44-015, and 45-455, and
all supplements and amendments thereto, is hereby withdrawn, effective
November 5, 2010.
In a final rule published elsewhere in this issue of the Federal
Register, FDA is amending the animal drug regulations to reflect the
withdrawal of approval of these NADAs.
Dated: October 8, 2010.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2010-27010 Filed 10-25-10; 8:45 am]
BILLING CODE 4160-01-P
